@article{da8eb88e98e94479a584843292105e58,
title = "Probing the proteome to explore potential correlates of increased Alzheimer's-related cerebrovascular disease in adults with Down syndrome",
abstract = "Cerebrovascular disease is associated with symptoms and pathogenesis of Alzheimer's disease (AD) among adults with Down syndrome (DS). The cause of increased dementia-related cerebrovascular disease in DS is unknown. We explored whether protein markers of neuroinflammation are associated with markers of cerebrovascular disease among adults with DS. Participants from the Alzheimer's disease in Down syndrome (ADDS) study with magnetic resonance imaging (MRI) scans and blood biomarker data were included. Support vector machine (SVM) analyses examined the relationship of blood-based proteomic biomarkers with MRI-defined cerebrovascular disease among participants characterized as having cognitive decline (n = 36, mean age ± SD = 53 ± 6.2) and as being cognitively stable (n = 78, mean age = 49 ± 6.4). Inflammatory and AD markers were associated with cerebrovascular disease, particularly among symptomatic individuals. The pattern suggested relatively greater inflammatory involvement among cognitively stable individuals and greater AD involvement among those with cognitively decline. The findings help to generate hypotheses that both inflammatory and AD markers are implicated in cerebrovascular disease among those with DS and point to potential mechanistic pathways for further examination.",
author = "Fahmida Moni and Petersen, {Melissa E.} and Fan Zhang and Lao, {Patrick J.} and Zimmerman, {Molly E.} and Yian Gu and Jos{\'e} Gutierrez and Batool Rizvi and Laing, {Krystal K.} and Igwe, {Kay C.} and Mithra Sathishkumar and David Keator and Howard Andrews and Sharon Krinsky-McHale and Elizabeth Head and Lee, {Joseph H.} and Florence Lai and Yassa, {Michael A.} and Rosas, {H. Diana} and Wayne Silverman and Lott, {Ira T.} and Nicole Schupf and Sid O'Bryant and Brickman, {Adam M.}",
note = "Funding Information: This work was supported by grants from the National Institutes of Health (U01 AG051412, U19 AG068054, K99 AG065506, U24 AG21886, UL1 TR001873). David Keator has received consulting fees from Amen Clinics Inc. Michael A. Yassa has received consulting fees from Eisai Cognito Therapeutics, LLC, CuraSen Therapeutics, Inc, and Enthorin Therapeutics, LLC. SEO holds numerous patents on precision medicine for neurodegenerative diseases and is the founding scientist of Cx Precision Medicine. Adam M. Brickman has received consulting fees from Keystone Heart, Regeneron, Cognition Therapeutics, and Flomenhaft Law firm. Other authors report no conflicts of interest in relation to the work presented here. We are grateful to the participants and their families and to the research staff. Publisher Copyright: {\textcopyright} 2022 the Alzheimer's Association.",
year = "2022",
month = oct,
doi = "10.1002/alz.12627",
language = "English",
volume = "18",
pages = "1744--1753",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "10",
}